Listed

Cumberland Pharmaceuticals Inc: Form 10-K for the period ended Dec 31, 2013

Filed with the SEC on Mar 11, 2014 and accepted by EDGAR at Mar 11, 2014, 17:18 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2013-12-31. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Revenue3 months2013-10-01 to 2013-12-31$8.2mus-gaap:SalesRevenueNet
Cost of revenue12 months2013-01-01 to 2013-12-31$5.4mus-gaap:CostOfGoodsSold
Research and development12 months2013-01-01 to 2013-12-31$5.6mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2013-10-01 to 2013-12-31−$2.5mus-gaap:OperatingIncomeLoss
Operating income12 months2013-01-01 to 2013-12-31−$3.8mus-gaap:OperatingIncomeLoss
Interest expense12 months2013-01-01 to 2013-12-31$103.4kus-gaap:InterestExpense
Income tax12 months2013-01-01 to 2013-12-31−$1.5mus-gaap:IncomeTaxExpenseBenefit
Net income3 months2013-10-01 to 2013-12-31−$1.5mus-gaap:NetIncomeLoss
Net income12 months2013-01-01 to 2013-12-31−$2.1mus-gaap:NetIncomeLoss
Diluted EPS3 months2013-10-01 to 2013-12-31−$0.08us-gaap:EarningsPerShareDiluted
Diluted EPS12 months2013-01-01 to 2013-12-31−$0.11us-gaap:EarningsPerShareDiluted
Basic EPS3 months2013-10-01 to 2013-12-31−$0.08us-gaap:EarningsPerShareBasic
Basic EPS12 months2013-01-01 to 2013-12-31−$0.11us-gaap:EarningsPerShareBasic
Diluted shares (weighted)12 months2013-01-01 to 2013-12-3118,332,997 sharesus-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
Operating cash flow12 months2013-01-01 to 2013-12-31$746.1kus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure12 months2013-01-01 to 2013-12-31$97.4kus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Share repurchases12 months2013-01-01 to 2013-12-31$4.8mus-gaap:PaymentsForRepurchaseOfCommonStock
Cash and equivalentsAt period end2013-12-31$40.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2013-12-31$68.7mus-gaap:AssetsCurrent
Total assetsAt period end2013-12-31$87.6mus-gaap:Assets
Current liabilitiesAt period end2013-12-31$7.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2013-12-31$8.3mus-gaap:Liabilities
Shareholders' equityAt period end2013-12-31$79.5mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001087294-14-000010. Last ingested by Listed: Nov 14, 2026, 23:39 ET. Listed shows no prices and gives no investment advice.